Discover
ENVB
Enveric Biosciences, Inc.
1.50
2 x 1.08
2 x 1.81
bid
ask
+
0.12
8.70%
2 @ 04:00 PM
1.50 +0.00 (0.00%)
| Ytd | -58.68% | |
| 1y | -89.84% |
1.38
day range
1.52
1.26
52 week range
17.64
| Open | 1.38 | Prev Close | 1.38 | Low | 1.38 | High | 1.52 | Mkt Cap | 6.04M |
| Vol | 129.69K | Avg Vol | 3.92M | EPS | -22.74 | P/E | N/A | Forward P/E | -0.22 |
| Beta | 0.47 | Short Ratio | 0.31 | Inst. Own | 7.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 04-23 | Earning | 08-15 | 50-d Avg | 2.45 | 200-d Avg | 4.15 | 1yr Est | 8.32 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.52 | -0.24 | 0.28 | 53.85% |
| 2024-08-12 | 2024-06 | -0.55 | -0.25 | 0.3 | 54.55% |
| 2024-05-14 | 2024-03 | -0.61 | -0.61 | N/A | N/A |
| 2024-03-25 | 2023-12 | -1.55 | -1.46 | 0.09 | 5.81% |
| 2023-11-13 | 2023-09 | -1.93 | -1.3 | 0.63 | 32.64% |
| 2023-08-14 | 2023-06 | 0 | -3.04 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-01-30 | HC Wainwright & Co. | Upgrade | Buy |
Profile
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-08 | COVENEY KEVIN MICHAEL | Chief Financial Officer | 186.50K | Stock Award(Grant) |
| 2024-10-08 | DEWITT SHEILA | Director | 27.85K | Stock Award(Grant) |
| 2024-10-08 | FACCHINI PETER JAMES | Officer | 130.86K | Stock Award(Grant) |
| 2023-01-24 | HAGEL JILLIAN MARIE | Officer | 35.80K | Stock Award(Grant) |
| 2023-01-24 | KANUBADDI AVANI | President | 48.35K | Stock Award(Grant) |
| 2024-10-08 | KEGLER GEORGE A. JR | Director | 48.05K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | AdvisorShares Investments, LLC | 367.05K | 113.78K | 3.61% |
| 2024-09-29 | Geode Capital Management, LLC | 217.89K | 67.55K | 2.14% |
| 2024-09-29 | Two Sigma Securities, LLC | 30.63K | 9.49K | 0.30% |
| 2024-09-29 | Virtu Financial LLC | 23.12K | 7.17K | 0.23% |
| 2024-09-29 | Vanguard Group Inc | 18.20K | 5.64K | 0.18% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 17.37K | 5.39K | 0.17% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | AdvisorShares Trust-AdvisorShares Psychedelics ETF | 628.31K | 194.78K | 6.18% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 163.68K | 50.74K | 1.61% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 42.37K | 13.14K | 0.42% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 18.20K | 5.64K | 0.18% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 10.35K | 3.21K | 0.10% |
| 2024-10-30 | Fidelity Total Market Index Fund | 463.00 | 143.00 | 0.00% |
Dividend
| Dividend | Date |
|---|---|
| 0.021 | 2008-04-23 |
Split
| Split | Date |
|---|---|
| 1 : 12 | 2025-10-28 |
| 1 : 15 | 2025-01-29 |
| 1 : 50 | 2022-07-15 |
| 1 : 4 | 2020-12-31 |
| 1 : 25 | 2019-11-25 |